Spectral AI NASDAQ: MDAI said it remains on track toward potential U.S. regulatory clearance and commercialization of its DeepView system for burn assessment, while reporting lower first-quarter research and development revenue tied to the completion of work under a federal contract.
Spectral AI, Inc. (MDAI) Q4 2025 Earnings Call Transcript
Spectral AI, Inc. (NASDAQ:MDAI ) Q2 2025 Earnings Conference Call August 12, 2025 5:00 PM ET Company Participants Dr.Michael DiMaio - Chairman of the Board Sara Prendergast - Corporate Participant Assistant General Counsel - Corporate Participant Vincent Stanley Capone - CFO, General Counsel & Corporate Secretary Conference Call Participants Carl Edward Byrnes - Northland Capital Markets, Research Division John D. Vandermosten - Zacks Small-Cap Research Ryan Benjamin Zimmerman - BTIG, LLC, Research Division Operator Good afternoon, everyone, and welcome to the Spectral AI Inc. Q2 2025 Financial Results Conference Call.
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| HPL Highlander Partners LP Highlander Partners LP | 900,000 | $2.29M | $1.64M | -$656,789.2 | -28.62% |
| AT Allison Tronnes Forum Financial Management LP | 60,501 | $125,322.92 | $110,111.82 | -$15,211.1 | -12.14% |
Nicholas McElroy Philip James Wealth Mangement, LLC | 12,000 | $27,360 | $21,840 | -$5,520 | -20.18% |
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RZ Ryan Zimmerman BTIG | 855.01 | $1,346.71 | $1,556.12 | $209.41 | 15.55% |
| Health Care Technology Industry | Healthcare Sector | Vincent Stanley Capone CEO | NASDAQ (CM) Exchange | 84757T105 CUSIP |
| US Country | 78 Employees | - Last Dividend | - Last Split | 6 Apr 2021 IPO Date |
Spectral AI, Inc. is at the forefront of artificial intelligence (AI) innovation, specializing in the field of medical diagnostics. Based in Dallas, Texas, the company's mission focuses on enhancing the speed and accuracy of treatment decisions for patients suffering from burns, diabetic foot ulcers, and similar complex wounds. By integrating AI into the process of medical diagnostics, Spectral AI, Inc. aims to revolutionize the way clinicians assess and approach wound care, ultimately contributing to more effective patient outcomes and the advancement of healthcare technology.
A cornerstone product of Spectral AI, Inc., DeepView leverages predictive diagnostics technology to provide clinicians with an objective and immediate assessment of a wound's healing potential. This AI-powered device is designed to help healthcare professionals make informed treatment decisions by evaluating numerous factors that influence wound recovery. The goal of DeepView is to improve the quality of wound care treatments, reduce recovery times, and minimize the risk of complications, thereby enhancing the overall patient care experience in cases of burns and diabetic foot ulcers.